Speaker: Anke-Hilse Maitland-van der Zee, PhD, Professor, Amsterdam University Medicine Center
Date: Thursday, May 25, 2023, noon-1 p.m.
Location: Tom and Linda Atkins Family Seminar Room, Roy Blunt NextGen Precision Health building
*Zoom option available
Many patients with asthma are well-controlled on existing medication; however, a group of severe asthma patients still have many complaints even if treated according to guidelines. Precision medicine can help identify the biological background of the disease in this group of patients and recognize so-called phenotypes. This can lead to the development of the optimal treatment for the individual patient. In this talk, results from many studies in both adult and pediatric asthma populations will be shown. Different omics layers (microbiome, transcriptome, metabolome) are used to identify phenotypes and possible first steps towards personalization of medicine for this patient group will be discussed. Furthermore, the collaboration in a large public-private partnership, Precision Medicine for More Oxygen (P4O2), will be discussed. What is it like to work in such a consortium and is this the future of research funding?
About the Speaker
Anke-Hilse Maitland-Van der Zee was trained as a pharmacist, clinical pharmacologist and epidemiologist. In 2016, she was appointed full professor in the Amsterdam UMC (Precision Medicine in Respiratory Disease). In 2005, she started to work at Utrecht University, first as an assistant professor and, in 2012, as an associate professor in Precision Medicine. From 2003 to 2005, she worked as a post-doc at the Human Genetics Center of the University of Texas in Houston. Her main research goal is to bring precision medicine into clinical practice. Moving away from using old-fashioned diagnostic labels, and instead using biomarkers to understand biological pathways and optimize therapy for the individual patient accordingly. She is among other principal investigators of the strategic public-private partnership Precision Medicine for More Oxygen (P4O2), and president of the Federation Innovative Medicine Research Netherlands (FIGON). She published more than 310 peer-reviewed articles.